MeiraGTx is a clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with serious diseases. We currently have four ongoing clinical programs, including three ocular indications and a salivary gland condition. Our initial focus on diseases of the eye, salivary gland and central nervous system is based on the significant unmet medical need coupled with the high potential gene therapy has to provide meaningful clinical benefit in these areas. With headquarters in New York and London, our global footprint provides us the opportunity to partner with leading institutions around the world, allowing us to deepen our understanding of diseases and their progression.
|Bank Name||MeiraGTx Holdings plc|
|Industry||Biotechnology: Biological Products|
|CEO||Dr. Alexandria Forbes|